Many scientists and biotechnology companies had given up on the idea of cancer immunotherapy in 1990s. Almost a decade after first detection of T cell suppression effect of CTLA4 the identity of its antibody was established. While they are found effective in many cancers including melanoma, lung cancer etc. immune checkpoint inhibitors have lent an important measure to manage recurrent and refractory ovarian cancer. This subject needs constant updating specially for students of ovarian cancer who are looking at this avenue of cure with much hope.